[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602007012072D1 - Orantagonisten - Google Patents

Orantagonisten

Info

Publication number
DE602007012072D1
DE602007012072D1 DE602007012072T DE602007012072T DE602007012072D1 DE 602007012072 D1 DE602007012072 D1 DE 602007012072D1 DE 602007012072 T DE602007012072 T DE 602007012072T DE 602007012072 T DE602007012072 T DE 602007012072T DE 602007012072 D1 DE602007012072 D1 DE 602007012072D1
Authority
DE
Germany
Prior art keywords
orantagonisten
tetrahydropyridines
compounds
relates
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007012072T
Other languages
English (en)
Inventor
Hamed Aissaoui
Christoph Boss
Markus Gude
Ralf Koberstein
Thierry Sifferlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of DE602007012072D1 publication Critical patent/DE602007012072D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
DE602007012072T 2006-04-26 2007-04-25 Orantagonisten Active DE602007012072D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2006051300 2006-04-26
PCT/IB2007/051522 WO2007122591A2 (en) 2006-04-26 2007-04-25 Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
DE602007012072D1 true DE602007012072D1 (de) 2011-03-03

Family

ID=38541955

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007012072T Active DE602007012072D1 (de) 2006-04-26 2007-04-25 Orantagonisten

Country Status (8)

Country Link
US (1) US7834028B2 (de)
EP (1) EP2013209B1 (de)
JP (1) JP2009535324A (de)
CN (1) CN101432285A (de)
AT (1) ATE496051T1 (de)
CA (1) CA2647077A1 (de)
DE (1) DE602007012072D1 (de)
WO (1) WO2007122591A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ550216A (en) 2004-03-01 2009-08-28 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
EP2059520B1 (de) * 2006-08-28 2010-02-24 Actelion Pharmaceuticals Ltd. 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
ES2380391T3 (es) 2006-12-22 2012-05-11 Actelion Pharmaceuticals Ltd. Derivados de 5,6,7,8-tetrahidro-imidazo[1,5-a]pirazina
MX2009010727A (es) * 2007-04-04 2009-10-26 Hoffmann La Roche Heterociclos como antagonistas de orexina.
MX2009012579A (es) 2007-05-23 2009-12-08 Merck & Co Inc Antagonistas piridil piperidina del receptor de orexina.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK2227455T3 (da) 2007-12-28 2012-01-23 Actelion Pharmaceuticals Ltd Trisubstitueret 3,4-dihydro-1H-isoquinolinforbindelse, fremgangsmåde til fremstillingen og dens anvendelse
BRPI0907627A2 (pt) * 2008-02-12 2015-07-21 Hoffmann La Roche Derivados de piperidina sulfonamidas
ATE555107T1 (de) * 2008-02-21 2012-05-15 Actelion Pharmaceuticals Ltd 2-aza-bicyclo-ä2,2,1-üheptan-derivate
RS59004B1 (sr) 2009-10-23 2019-08-30 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
EP2516437B1 (de) 2009-12-21 2014-01-29 Novartis AG Disubstituierte heteroarylkondensierte pyridinederivate
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2508511A1 (de) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitoren der Virenreplikation, Verfahren zu deren Herstellung und deren therapeutische Verwendung
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
BR112014019426A8 (pt) 2012-02-07 2017-07-11 Eolas Therapeutics Inc Prolinas/ piperidinas substituídas como antagonistas do receptor de orexina
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
GB201308236D0 (en) 2013-05-08 2013-06-12 Givaudan Sa Improvements in or relating to organic compounds
WO2014205782A1 (en) 2013-06-28 2014-12-31 Givaudan Sa Organic compounds
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
MX2017005862A (es) 2014-11-10 2017-06-26 Givaudan Sa Mejoras en o que se relacionan con compuestos organicos.
WO2016074696A1 (en) * 2014-11-10 2016-05-19 Givaudan Ag Perfume ingredients and perfume preparations containing same
LT3414241T (lt) 2016-02-12 2022-08-25 Astrazeneca Ab Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai
CN115154470B (zh) 2016-03-10 2024-09-20 詹森药业有限公司 使用食欲素-2受体拮抗剂治疗抑郁症的方法
WO2017194548A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
CN111494376A (zh) * 2020-06-15 2020-08-07 牡丹江医学院 一种用于治疗牙龈炎的药物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60108236T2 (de) 2000-03-14 2005-12-22 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisochinolin-derivate
JPWO2001085693A1 (ja) * 2000-05-11 2004-01-08 萬有製薬株式会社 Ｎ−アシルテトラヒドロイソキノリン誘導体
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
PT1501804E (pt) 2002-04-26 2009-10-29 Hoffmann La Roche Derivados de isoquinolina
US6709392B1 (en) * 2002-10-10 2004-03-23 Koninklijke Philips Electronics N.V. Imaging ultrasound transducer temperature control system and method using feedback
AU2004224156B2 (en) 2003-03-26 2010-08-12 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
NZ550216A (en) * 2004-03-01 2009-08-28 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
US20090082394A1 (en) * 2006-03-15 2009-03-26 Actelion Pharmaceuticals, Ltd. Tetrahydroisoquinoline Derivatives to Enhance Memory Function

Also Published As

Publication number Publication date
CN101432285A (zh) 2009-05-13
ATE496051T1 (de) 2011-02-15
US7834028B2 (en) 2010-11-16
EP2013209B1 (de) 2011-01-19
US20090099228A1 (en) 2009-04-16
EP2013209A2 (de) 2009-01-14
CA2647077A1 (en) 2007-11-01
JP2009535324A (ja) 2009-10-01
WO2007122591A3 (en) 2008-01-10
WO2007122591A2 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
DE602007012072D1 (de) Orantagonisten
ATE500250T1 (de) Azetidinverbindungen als orexin-rezeptor- antagonisten
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
BRPI0913806A2 (pt) "composição"
EA200870409A1 (ru) Антагонисты киназы pi3
ATE524466T1 (de) 3-azabicycloä3.3.0üoktanverbindungen
EA201170884A1 (ru) Производные пиперидина, пригодные в качестве антагонистов орексина
EA201000844A1 (ru) Связывающие wise агенты и эпитопы
BRPI0910229A2 (pt) Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
DK1963369T3 (da) Il-21-antagonister
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
MA30948B1 (fr) MYRTILLE NOMME " DrisBlueThree "
MX2010001575A (es) Derivados de 1,2-diamido-etileno como antagonistas de orexina.
MA30949B1 (fr) MYRTILLE NOMME "DrisBlueTwo"
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
ATE506343T1 (de) Malonamide als orexin-antagonisten
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
BRPI0819281A2 (pt) Composições de fibra inorgânica
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
DK2364185T3 (da) Disubstituerede phthalazin-hedgehog-pathway-antagonister
BRPI0907062A2 (pt) "hidrociclone"